KidneyCure Ltd. is an Israeli biotechnology company developing a disruptive regenerative cell-therapy approach to treat advanced Chronic Kidney Disease (CKD) patients. The technology was initially developed by Prof. Dekel at the Sheba Medical Center in Israel, rated recently as one of the ten best hospitals in the world by Newsweek.
Mission: KidneyCure’s game changing cell-therapy approach is aiming to prevent progression of CKD towards End Stage Renal Disease (ESRD) and by doing so, to help hundreds of thousands CKD patients to live longer, better quality and more productive lives.
KidneyCure’s first product, 3DAN™-001, free-floating 3-Dimensional Adult Nephroforms-based therapy, aims to maintain kidney function and to delay the need for dialysis or renal transplantation. 3DAN™ is based on autologous, renal epithelial adult cell forms suspended in a proprietary formulation adapted for delivery into the kidney. Upon administration, 3DAN ™ is expected to prevent the formation of renal fibrotic tissue, reduce inflammation, significantly improve kidney function, and delay the progression of the disease.